Navigation Links
OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
Date:4/28/2009 

    FDA confirms durable pain palliation as an acceptable primary endpoint
    for a regulatory submission in support of market approval

BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a second Phase 3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC), via the Special Protocol Assessment (SPA) process. The FDA has agreed that the design and planned analysis of our Phase 3 trial featuring durable pain palliation as the primary endpoint adequately addresses the objectives necessary to support a regulatory submission.

"We have now received confirmations on two separate Phase 3 trial designs from the FDA via the SPA process, each in second-line treatment of advanced prostate cancer," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "One trial design evaluates overall survival benefit while the second trial design evaluates reduction in pain as the primary endpoint. Having evaluated both of these endpoints in our Phase 2 trials, we are well positioned to re-evaluate each of these endpoints in larger Phase 3 registration trials."

"The FDA's acknowledgement of pain in addition to survival as key endpoints for market approval supports the basis of our OGX-011 development program for advanced prostate cancer," added Cormack. "Although we observed a positive effect on PSA in our Phase 2 trials of OGX-011, we recognize that PSA response has not been shown to correlate to a clinical benefit and therefore is not an acceptable endpoint for FDA approval. Our focus remains on survival and pain palliation, both endpoints that FDA has confirmed are appropriate for marketing approval, and both endp
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... 2013 RURO Inc. is pleased ... a versatile refinement to the smart management solution. ... its advanced methodical management for transgenic animal colonies, ... The network-based platform provides user access with a ... continuing to emphasize streamlined tasks, such as animal ...
(Date:5/16/2013)... 2013 The Stirling Ultracold Model ... Inc., Athens, OH, USA, won the Outstanding New Product ... Society for Biological and Environmental Repositories (ISBER) at their ... one product annually, recognizes the company’s development and introduction ... The award was presented to Global Cooling’s CEO ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
Breaking Biology Technology:Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... Metamark Genetics, Inc., a privately held oncology molecular ... Straley as the company,s President, Chief Executive Officer, and ... Weg, a Metamark co-founder who previously served as interim ... Board of Directors. Mr. Straley brings twenty ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ... targeting the extracellular matrix for the ... reported financial results for the third quarter ended ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO ) ...
... first in a series of video programs called Innovation ... O,Brien and currently airing nationally on the the Science ... what happens when genius meets possibility: stories about some ... The 26-part video series is produced by CBS ...
Cached Biology Technology:Metamark Genetics, Inc. Announces New Chief Executive Officer 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 7
(Date:5/16/2013)... predict the stability of today,s largest ice sheets in Greenland ... years ago, for example when Earth was going through ... a high sea level due to ice sheet collapse at ... that if the world,s largest ice sheets collapsed in the ... modern, progressively warming world. , However, a new groundbreaking ...
(Date:5/16/2013)... players and athletes choose to wear the color red ... in Psychological Science , a journal of the ... to do with their testosterone levels. , The new ... University of Sunderland and colleagues, demonstrated that males who ... had higher testosterone levels than other males who chose ...
(Date:5/16/2013)... entirety of an individual,s DNA is examined to look ... health problems is a massively useful technology for diagnosing ... problems if used incorrectly, say new recommendations from the ... today (16 May 2013) in the European Journal ... genome and on exome* sequencing and analysis are now ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2High-testosterone competitors more likely to choose red 2European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2
... University of Alabama at,Birmingham (UAB) have identified the ... autoimmune disorders like rheumatoid,arthritis and lupus. The ... an immunity protein. UAB researchers pinpointed an ... aside from its commonly known effects within ,immunity. ...
... Just as additives help gasoline burn cleaner, a research ... The FASEB Journal shows that the food industry could ... with fatty foods. These meal additives would be based ... polyphenols (natural compounds in red wine, fruits, and vegetables) ...
... includes an article by biologist Edward O. Wilson that ... advanced social organization in some ants, bees, and wasps ... high level of social organization called eusociality, found in ... result of natural selection on nascent colonies of species ...
Cached Biology News:Protein's new role discovered in autoimmune disease 2Insects' 'giant leap' reconstructed by founder of sociobiology 2
...
... designed for enhanced translation of cloned sequences in ... lysate. The maps for pCITE-2b(+) and pCITE-2c(+) are ... pCITE-2b(+) is a 3793 bp plasmid; it lacks ... I sites. Subtract 7 bp from all sites ...
...
...
Biology Products: